EUVIMEDEUVIMED entdecken
Crossref

Initial clinical experience with RADA16 as a novel therapeutic for severe haemorrhagic radiation cystitis: a preliminary feasibility case series

Petre Cristian Ilie, Anne Carrie, Yacine Touati, Robert Mills, Croitoru Radu, Claudiu Tanase, Ruth Doherty, Will Finch, David Manson-Bahr, Fiona Richardson, Tom Dymond, Lee Smith

International Urology and Nephrology · 2026

DOI: 10.1007/s11255-026-05219-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Urology and Nephrology, 2026. Verfasst von Petre Cristian Ilie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Urology Department, The Queen Elizabeth Hospital Foundation Trust, King's Lynn, UK. petre.ilie@nnuh.nhs.uk. Hauptthemen laut MEDLINE: Cystitis, Hemorrhagic, Radiation Injuries, Peptides, Cystitis. Die Arbeit nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Haemorrhagic radiation cystitis (HRC) is a challenging complication of pelvic radiotherapy, often resistant to conventional treatments. AIMS: To evaluate the clinical efficacy and safety of RADA16, a self-assembling peptide, in managing severe HRC. METHODS: A preliminary feasibility case series of five consecutive patients treated at two UK hospitals. All patients had persistent haematuria despite standard interventions and received RADA16 via flexible or rigid cystoscopy. RESULTS: The findings from the cases suggest that all patients have experienced at least a partial or early resolution of haematuria and no adverse effects were reported. In most cases, two applications of RADA16 were sufficient. The longest patient followed up was still symptom free at 3 years. DISCUSSION: This preliminary feasibility case series has demonstrated early efficacy for RADA16 in the management of HRC. CONCLUSIONS: RADA16 is a potentially promising minimally invasive treatment for refractory HRC. Further trials are warranted to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystitis, HemorrhagicRadiation InjuriesPeptidesCystitisHumansFeasibility StudiesFemaleAgedMiddle AgedMaleHematuriaSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

HaematuriaHaemorrhagic cystitisPuraBondPuraStatRADA16Radiation cystitis

Substanzen

Peptides

Autor:innen und Institutionen

  • Urology Department, The Queen Elizabeth Hospital Foundation Trust, King's Lynn, UK. petre.ilie@nnuh.nhs.uk.
  • Urology Department, Norfolk and Norwich University Hospital, Norwich, UK.
  • Urology Department, The Queen Elizabeth Hospital Foundation Trust, King's Lynn, UK.
  • Research and Innovation Department, The Queen Elizabeth Hospital Foundation Trust, King's Lynn, UK.
  • Centre for Health Performance and Wellbeing, Anglia Ruskin University, Cambridge, CB1 1PT, UK.
  • Faculty of Medicine, Department of Public Health, Biruni University, Istanbul, Turkey.

Zitieren

APA

Ilie, P. C., Carrie, A., Touati, Y., Mills, R., Radu, C., Tanase, C., Doherty, R., Finch, W., Manson-Bahr, D., Richardson, F., Dymond, T., & Smith, L. (2026). Initial clinical experience with RADA16 as a novel therapeutic for severe haemorrhagic radiation cystitis: a preliminary feasibility case series. International Urology and Nephrology. https://doi.org/10.1007/s11255-026-05219-9

Vancouver

Ilie PC, Carrie A, Touati Y, Mills R, Radu C, Tanase C, et al. Initial clinical experience with RADA16 as a novel therapeutic for severe haemorrhagic radiation cystitis: a preliminary feasibility case series. International Urology and Nephrology. 2026. doi:10.1007/s11255-026-05219-9

BibTeX
@article{Ilie2026,
  author = {Ilie, Petre Cristian and Carrie, Anne and Touati, Yacine and Mills, Robert and Radu, Croitoru and Tanase, Claudiu and Doherty, Ruth and Finch, Will and Manson-Bahr, David and Richardson, Fiona and Dymond, Tom and Smith, Lee},
  title = {Initial clinical experience with RADA16 as a novel therapeutic for severe haemorrhagic radiation cystitis: a preliminary feasibility case series},
  journal = {International Urology and Nephrology},
  year = {2026},
  doi = {10.1007/s11255-026-05219-9}
}
Kostenlos starten →